Ann: Preclinical Data from Osteoarthritis Animal Study, page-18

They said 2021 is the year they LEAP, not "Q1 2021"

Regardless, it would have been nice if the announcement was worded far better. The gentleman quoted in the announcement, Dr Angus Tester, won't be the last doctor who speaks too bluntly for the civilian taste.

Rather than opening with the far-too-blunt, and wildly unnecessary, "we were surprised to see no beneficial effect of either Plexaris or Cevaris over control," they should have said something like:

"Regarding subject response, we found the rat's knee joints were damaged beyond repair, with no obvious cartilage cells available, therefore it was not possible to identify if the rats would respond to the exosome treatment. Now that safety, toleration, and lack of toxicity have all been proven, we will be able to test subject response in the next phase of trials."

That wasn't hard, was it?

To be fair, however, there needs to be administrative editorialisation before the announcement is released to the investing public.